This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.
Otherwise, enjoy the column!
© 2019 Mott Capital Management, LLC. Use, publication or reproduction in any media prohibited without the permission of the copyright holder.
Join our 1,434 Daily Subscribers And Get This FREE Commentary In Your E-Mail!
Michael Kramer and the clients of Mott Capital own NXPI, AAPL, and NFLX
Thursday, February 7
- S&P 500 pointing to a lower opening of 17 points
- 10-Year 2.67%
- Dollar Index 96.63
- Oil $53.61
- Japan Nikkei -59 bps
- China Shanghai – Closed
- Hong Kong Hang Seng – Closed
- South Korea Kospi -4 bps
- German Dax -1.36%
- UK FTSE -1 bps
Asian Markets have stalled out this week, with China closed. Japan has stalled out at 20,951.
The KOSPI has also stalled out at resistance around 2,210. That also happens to be a downtrend. The RSI has also reached overbought levels.
It is tough to confirm the moves in South Korea and Japan without China open. But at least for now they have some tough levels of resistance. But again we will need to see how these develop over the coming days.
S&P 500 (SPY)
The S&P is pointing to a lower opening today with a decline of about 17 points. Support for the index comes around 2,716 and then 2,690. With yesterday’s close, the chart had appeared to be setting up for a breakout today, but that is not what the opening is pointing to at the moment. It is a bit of a disappointment to me, but the good news is that we should gap lower, and that is likely to result in a move higher to fill the gap at some point later today or the days to follow. Overall I don’t think today puts into jeopardy the move to 2,800.
Biotech appears to be stalling out around resistance at $85.25, and now we need to watch support at $82.25, a drop below that level could result in a decline back to $78.75.
Twitter is falling in the pre-market after guiding to a weaker revenue outlook. Also, the company said it would discontinue giving Monthly Active Users, something the market is not going to like. Support is going to be around $30.20.
NXP Semi (NXPI)
NXPI is falling in the pre-market after it reported results. I thought the results were good, guidance was a bit light, but certainly no worse than other names in the group. The stock has come a long way, so perhaps a pullback is due. But still, I thought the results based on the PR was fine. The conference call is pointing to weakness in China as the biggest issue.
Square is looking to open lower and has really struggled to get over $75, and I still think the stock is likely heading towards $68.
Netflix is pointing to a lower opening as well, but there is a critical uptrend in place. Should the uptrend break it could result in a decline to around $338.
Amazon is the on the cusp of a breakdown which could send the stock sharply lower. $1620 continues to be the line in the sand, with the $1520 on the horizon.
Apple shares are still trending higher, but for now, support comes around $164, should it pull back some.
Overall things seem to be intact. I don’t expect today’s weakness to be the start of something more severe. I don’t. Sorry for the bears out there.
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future results.